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ABSTRACT 
In research ethics, provision of potential benefits to study participants is
linked to the principles of beneficence and distributive justice. However, in
most research ethical codes the notion of benefit is only superficially elabor-
ated which is extended in vague and general benefit assessments in research
proposals and in Research Ethical Committee’s (REC) recommendations.
The issue gains additional importance in collaborative projects where re-
searchers, study populations and donors from both developing and devel-
oped countries are involved. We introduce a checklist for planning and as-
sessment of benefits as part of research ethics and suggest as a first step in
unfolding the concept of benefits that research project and RECs as a min-
imum should address who (the target groups), when (the period of time dur-
ing which the services are planned to be rendered) and what (the nature of
the benefits). 
It is a common view that research ethics rest on the key principles of
respect, beneficence and justice [1]. Respect for persons encom-
passes respect for autonomy as well as “protection of persons with
impaired or diminished autonomy”. “Beneficence refers to the ethical
obligation to maximize benefits and to minimize harms” whereas
justice “refers primarily to distributive justice, which requires the
equitable distribution of both the burdens and the benefits of par-
ticipation in research” [1]. Sometimes non-maleficence (“a norm of
avoiding the causing of harm”) is mentioned as a fourth principle
[1, 2]. Schüklenk [3] as well as Beauchamp & Childress [2] point out
that there are alternative conceptual ethical frameworks at hand
such as utilitarianism, deontological bioethics, liberal individualism
and communitarianism.
Within the discourse of medical research ethics, the discussion of
benefits concentrates to a large extent on the so-called standard of
care issue. Thus, the Helsinki Declaration [4] demands that the
services rendered should be of the best global standard. This has
been widely debated and others [5, 6] take the stand that provision
only according to local standards is justified. Some scholars advocate
for a broader definition of standard of care (including sustainability
and scaling up) [7] and a partnership approach to “provide positive
benefits to society” [8].
As a large number of studies today are implemented for commer-
cial rather than health promotion (e.g. trials to prolong patent pro-
tection of drugs with minimal medical benefit), there is an increased
need to address the concept of benefit and quantify it as an outcome
(e.g. number of gained quality adjusted life years). However, aspects
of benefit are generally less elaborated in research proposals and in
assessments conducted by Research Ethics Committees (REC) than
other research ethical issues such as informed consent and avoid-
ance of harm. The aim of the present article is to initiate a discussion
on standards for benefit assessments by suggesting a checklist that
will allow a more systematic and explicit description of potential
benefits in research proposals and subsequent reviews. Clarification
of benefits is a prerequisite for an assessment of beneficence in
which the balance between potential harms and benefits is gauged.
The focus here is on health projects where developed countries
sponsor and implement research in developing countries with re-
searchers from both sides to participate making issues of potential
benefits more conspicuous.
HOW THE ISSUE OF BENEFITS IS ADDRESSED 
IN INTERNATIONAL RESEARCH ETHICAL CODES
Among the numerous international ethical codes (laws, directives,
conventions, declarations and guidelines) descriptions of the benefit
complexity are scarcely met. Here six prominent examples of central
codes are addressed.
The seventh version of the Declaration of Helsinki with notes of
clarification [4] mentions in point 6 that “understanding of the
aetiology and pathogenesis of disease” is “the primary purpose of
medical research involving human subjects”. In point 19 it is expli-
citly stated that “Medical research is only justified if there is a reason-
able likelihood that the population in which the research is carried
out stand to benefit from the results of the research”. The obligation
to publish “negative as well as positive results” is also mentioned. In
point 30 the declaration states that “every patient entered into the
study should be assured of access to the best-proven prophylactic,
diagnostic and therapeutic methods identified by the study” – and
this point is further emphasized in the clarifying note of 2004.
The Council for International Organisations of Medical Sciences
(CIOMS) speaks in its International Ethical Guidelines for Biomed-
ical Research Involving Human Subjects [1] in guideline 5, points 10
and 11, of “the direct benefits” for participating subjects and “ex-
pected benefits” to the community or to society at large. Further in
point 21 it is stated that if “commercial products may be developed
from biological specimens it ought to be considered whether the
participant will receive monetary or other benefits”. The guidelines
also speak in point 23 on “the investigator’s responsibility to provide
medical services to the participant”. An overall statement of direct
and indirect benefits is found in guideline 8. Guideline 20 describes
the need to provide research and ethical capacity building as part of
externally sponsored collaborative projects, and guideline 21 draws
the attention to the ethical obligation of external sponsors to pro-
vide healthcare services. As a whole the CIOMS guidelines deal
more with risks and protection than with benefit for participants. 
The Council of Europe’s Convention on Human Rights and Bio-
medicine [9] deals primarily with the protection perspective of par-
ticipants, and also uses the general term benefit. The Explanatory
Report [10] does not add any specification of this general term. The
same is true for the Additional Protocol to the Convention on
Human Rights and Biomedicine on Biomedical Research [11].
In its summary of the Commission’s six publications, the U.S. Na-
tional Bioethics Commission [12] uses the terms risks and potential
benefits, and their absolute and relative influence on overall research
ethics decisions. The primary target group of the guidelines is the
project participants (Recommendation 4.1) whereas the society is
only mentioned as an overall term.
The UNESCO Universal Declaration on Bioethics and Human
Rights [13] has a broad international perspective. Benefit is defined
as “direct and indirect benefits to patients, research participants and
other affected participants“ (Article 4). “Cultural diversity and plur-
alism have to be given due regard”, but not “to be invoked to in-
fringe upon human dignity, human rights and fundamental
freedoms” (Article 12), and the perspective of “solidarity among hu-
man beings and international cooperation towards that end are to
be encouraged” (Article 13). Both statements are relevant for benefit
and harm when biomedical research takes place in developing coun-
tries. These global perspectives of benefit are even more precisely
stated in Article 15, “Sharing of benefits”, and in Article 21, “Trans-
national practices”, Sections c-e.
The Nuffield Council of Ethics’ report [5], provides a detailed
analysis of various global perspectives of research ethics including
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benefits. The working party behind the publication emphasizes
clearly that the researchers in developing countries need to obtain a
benefit via “the development of local expertise in the provision of
healthcare and in healthcare research”, and that such a benefit
“should be an integral component of any proposed research”. 
When a research project is over, the Nuffield report strongly advo-
cates three aspects of benefit: 1) the monitoring of “possible long-
term deleterious outcomes arising from the research”, 2) “the possi-
bility of providing participants with the intervention shown to be
the best”, and 3) “the possibility of introducing and maintaining the
availability to the wider community of treatment shown to be suc-
cessful”. 
The report summarizes the ethical dilemmas related to the con-
trol group, which should be offered the benefit of “a universal stand-
ard of care for the disease being studied; where it is not appropriate
to offer a universal standard of care, the minimum standard of care
that should be offered to the control group is the best intervention
available for that disease as part of the national public health sys-
tem”. Further the report stresses that “before research begins, agree-
ment should be reached about the standard of care that should be
provided to participants in research who already have or who de-
velop diseases other than the diseases being studied”. “The min-
imum standard of care that should be offered” is also here “the best
intervention available as part of the national public health system”.
Common for all six codes are the brief and general description of
required benefits as outcomes of a research project.
BENEFITS AS PART OF RESEARCH ETHICS
If a project is based on an original scientific idea and includes an ap-
propriate methodology, relevant variables and reaches the planned
termination, there will always be a potential scientific benefit. But,
in addition to the standard questions of research ethics, we suggest
that an analysis of the potential benefits should be included in a
project proposal and should be part of ethical reviews. 
We contend that determination of benefit in a research project
should as a minimum address three dimensions:
– Who? The target group (varying from the study participants ex-
posed to the active intervention, over the possible control group,
to other members of the study community, the nation or the glo-
bal community of relevant patients and humankind in general).
– When? The period of time during which the services are planned
to be rendered (varying from the direct effect of intervention
during the trial to long-term provision beyond the duration of
the project per se).
– What? The nature of benefit provided (varying from the specific
intervention on trial, over provision of clinical care for critical
medical conditions and basic medical services in general, to pro-
vision of even non-medical assistance such as improved water
supply or schools in the study community).
These three dimensions can be seen as continua along which bene-
fits may be perceived in terms of the beneficiaries, the duration, and
the sort of benefit provided. In order to facilitate the analysis, a
checklist of questions is provided below.
A CHECKLIST FOR POTENTIAL BENEFIT 
IN A HEALTH RESEARCH PROJECT
The list of questions is structured according to the first dimension,
the target group, addressing the study participants, community
members at large (local, regional, or national community mem-
bers), and the researchers involved in the study. Table 1 illustrates
the questions of relevance for the three target groups.
Study participants 
1. Has it been ensured that study participants (both the interven-
tion and the control group of a trial) will get access to the new
diagnostic or therapeutic tool if found more efficient than the
standard? If yes, for how long? 
2. Will the project provide (emergency or general) clinical services
to the study participants apart from what is directly related to the
procurement of the study variables? If yes, to which extent and
for how long?
3. Will the project provide non-medical services (e.g. related to
education, monetary or other material benefits) to the study par-
ticipants? If yes, what, to which extent and for how long?
4. Has the protocol considered giving feedback to the participants
about the general research results?
5. Has the protocol considered participants’ right to receive feed-
back about their personal results along with suggestions about
clinical consequences for themselves?
6. Does the project include elements of capacity building for the
study participants?
Community members (local, regional, national)
Questions 1-4 and 6 apply equally to other community members
not participating in the study although a borderline must be drawn
depending on the magnitude of the study. However, an expansion
could be made to question 4: Has it been considered how the study
findings are to be disseminated to relevant public health or medical
stakeholders at national and international level in order to achieve
utilisation where relevant (e.g. changed policies or procedures)? 
Additionally for communities it should be asked: 7. Will the com-
munity (local, regional, national) receive a share of any profits
derived from industrial processing of their belongings (e.g. material
from biobanks), developed during a research project? If yes, to
which extent and in which way?
Researchers participating in the project
Questions 6 and 7 should also be asked regarding this group. Op-
tions for both scientific and technical elements of capacity building
should be explored for team members from developing countries.
Additionally for participating researchers, the following question
should be asked: 8. Is the collaboration between researchers from
the developed and the developing countries involved based on
equity (e.g. in terms of intellectual property rights and equal access
to co-authorship)?
It is assumed that the altruistic satisfaction of benefiting fellow
patients in a general way and making a contribution to increased
general knowledge is known to and appreciated by the participants.
This pertains to new knowledge about diagnostic or therapeutic
Table 1. A graphic visualisation of 
questions for planning and assessing 
benefits in connection with research 
projects. Grey cells indicate non-
relevance.
Study Community
Benefits  Questions participants members Researchers
Access to new tools . . . . . . . . . . . . . . . . . . . . . . . .  1   
Provision of clinical services . . . . . . . . . . . . . . . . .  2   
Provision of other services  . . . . . . . . . . . . . . . . . .  3   
Feedback about research findings . . . . . . . . . . . .  4   
Feedback about personal results . . . . . . . . . . . . .  5   
Capacity building  . . . . . . . . . . . . . . . . . . . . . . . . .  6   
Rights to share profits from research  . . . . . . . . .  7   
Equity between researchers . . . . . . . . . . . . . . . . .  8   
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tools as well as basic insights into pathogenesis or taxonomy of the
diseases studied.
Not all parts of the checklist are relevant for all research protocols
involving humans in developing countries. Both the types of studies
and the political and economic conditions in the collaborating
recipient country necessitate a selective use of the checklist. But dur-
ing the planning and assessment of such studies it is recommended
to go through the list in order to specify the generic indications of
the international research ethical codes.
CONCLUSION
Based on the principles of beneficence and distributive justice, pro-
vision of potential benefits for study participants should be a key
criterion in planning and assessing health research projects involv-
ing humans. Yet, whereas the majority of international research
ethical codes deal with informed consent in great detail, benefits are
often referred to in more general terms and without addressing the
many practical dilemmas. The issue is especially conspicuous in
projects comprising participants from both developing and devel-
oped countries. We have introduced a list of questions that allows a
systematic analysis of benefits and facilitates a more elaborate and
practical description. 
It comprises three main analytic dimensions: 1) the target groups
(who?), 2) the period of time during which the services are planned
to be rendered (when?), and 3) the nature of the benefits provided
(what?) – all of which are continua along which the potential bene-
fits can be perceived and organised. How the various points on the
checklist are eventually assessed in relation to a given project de-
pends on factors such as the type of research, the context in which it
is implemented and the parties involved. 
Thus, we provide a tool that may facilitate an evaluation, but we
do not conduct the evaluation ourselves. It is our hope that the
views presented here will initiate a discussion on standards for bene-
fit assessment, and that the checklist will assist both researchers in
the planning phase of a study and RECs in dealing with ethical re-
views.
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